Clinical Research Study|Articles in Press

Long-Term Follow-Up After Acute Myocardial Infarction According to Beta-Blocker Dose

Published:February 20, 2023DOI:



      Our purpose was to examine the association between beta-blocker dose and mortality following acute myocardial infarction.


      This nationwide cohort study enrolled all patients admitted for first-time acute myocardial infarction in Denmark between July 1, 2004 and December 31, 2014, using the Danish National Patient Registry. Patients alive 15 days after admission were followed until death, emigration, or December 31, 2014. Patients were categorized according to daily beta-blocker consumption (0%, >0%-12.5%, >12.5%-25%, >25%-50%, >50%-100%, or >100% of the currently recommended target dose) based on prescriptions registered in the Danish National Database of Reimbursed Prescriptions. Doses were continuously updated during follow-up. Mortality rate ratios (MRRs) were computed and adjusted for confounders using Cox proportional hazard regression.


      Among 65,125 patients followed, any beta-blocker dose was associated with significant mortality reduction compared with no treatment (adjusted MRR ≤ 0.92 [95% confidence interval {CI}: 0.86-0.98]). The largest reduction was observed within the first year for beta-blocker doses >25%-50% (adjusted MRR = 0.55 [95% CI: 0.50-0.60]). After 1 year, doses >50%-100% were associated with the largest mortality reduction (adjusted MRR = 0.58 [95% CI: 0.50-0.67]), but it did not differ significantly from that associated with doses >25%-50% (adjusted MRR = 0.68 [95% CI: 0.61-0.77]).


      Any beta-blocker dose was associated with significant mortality reduction following acute myocardial infarction compared with no treatment. Doses >25%-50% of the currently recommended target dose were associated with maximal mortality reduction within the first year after acute myocardial infarction, suggesting that higher doses are unnecessary.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Amsterdam EA
        • Wenger NK
        • Brindis RG
        • et al.
        2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes.
        J Am Cardiol Coll. 2014; 64: e139-e228
        • O'Gara PT
        • Kushner FG
        • Casey DE
        • et al.
        2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction.
        J Am Cardiol Coll. 2013; 61: e78-140
        • Hjalmarson A
        • Elmfeldt D
        • Herlitz J
        • et al.
        Effect on mortality of metoprolol in acute myocardial infarction: A double-blind randomized trial.
        Lancet. 1981; 2: 823-827
        • The CAPRICORN Investigators
        Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
        Lancet. 2001; 357: 1385-1390
        • CIBIS-II Investigators and Committees
        The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial.
        Lancet. 1999; 353: 9-13
        • Wilcox RG
        • Roland JM
        • Banks DC
        • et al.
        Randomized trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction.
        Brit Med J. 1980; : 885-888
        • Β-blocker Heart Attack Trial Research Group
        A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results.
        JAMA. 1982; 247: 1707-1714
        • Goldberger JJ
        • Bonow RO
        • Cuffe M
        • et al.
        Β-blocker use following myocardial infarction: low prevalence of evidence-based dosing.
        Am Heart J. 2010; 160: 435-442
        • Arnold SV
        • Spertus JA
        • Masoudi FA
        • et al.
        Beyond medication prescription as performance measures.
        J Am Coll Cardiol. 2013; 62: 1791-1801
        • Goldberger JJ
        • Bonow RO
        • Cuffe M
        • et al.
        Effect of beta-blocker dose on survival after acute myocardial infarction.
        J Am Coll Cardiol. 2015; 66: 1431-1441
        • Grall S
        • Biere L
        • Nezet ML
        • et al.
        Relationship between beta-blocker and angiotensin-converting enzyme inhibitor dose and clinical outcome following acute myocardial infarction.
        Circ J. 2015; 79: 632-640
        • Li C
        • Sun Y
        • Shen X
        • et al.
        Relationship between beta-blocker therapy at discharge and clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
        J Am Heart Assoc. 2016; 5 (pii)e004190
        • Pedersen SB
        • Nielsen JC
        • Bøtker HE
        • et al.
        Beta-blocker therapy early after myocardial infarction: a comparison between medication at hospital discharge and subsequent pharmacy-dispensed medication.
        Drugs Real World Outcomes. 2016; 3: 279-288
        • Allen JE
        • Knight S
        • McCubrey RO
        • et al.
        Beta-blocker dosage and outcomes after acute coronary syndrome.
        Am Heart J. 2017; 184: 26-36
        • Mars K
        • Wallert J
        • Held C
        • et al.
        Association between beta-blocker dose and cardiovascular outcomes after myocardial infarction: insights from the SWEDEHEART registry.
        Eur Heart J Acute Cardiovasc Care. 2021; 10: 372-379
        • Goldberger JJ
        • Subačius H
        • Marroquin O
        • et al.
        OBTAIN (Outcomes of Beta-Blocker Therapy After Myocardial Infarction) Investigators. One-year landmark analysis of the effect of beta-blocker dose on survival after acute myocardial infarction.
        J Am Heart Assoc. 2021; 10e019017
        • Korhonen MJ
        • Robinson JG
        • Annis IE
        • et al.
        Adherence tradeoff to multiple preventive therapies and all-cause mortality after acute myocardial infarction.
        J Am Coll Cardiol. 2017; 70: 1543-1554
        • Butler J
        • Arbogast PG
        • BeLue R
        • et al.
        Outpatient adherence to beta-blocker therapy after acute myocardial infarction.
        J Am Coll Cardiol. 2002; 40: 1589-1595
        • Desta L
        • Khedri M
        • Jernberg T
        • et al.
        Adherence to beta-blockers and long-term risk of heart failure and mortality after a myocardial infarction.
        Eur Soc Cardiol Heart Fail. 2021; 8: 344-355
        • Schmidt M
        • Pedersen L
        • Sørensen HT.
        The Danish Civil Registration System as a tool in epidemiology.
        Eur J Epidemiol. 2014; 29: 541-549
        • Schmidt M
        • Schmidt SA
        • Sandegaard JL
        • et al.
        The Danish National Patient Registry: a review of content, data quality, and research potential.
        J Clin Epidemiol. 2015; 7: 449-490
        • Johannesdottir SA
        • Horváth-Puhó E
        • Ehrenstein V
        • et al.
        Existing data sources for clinical epidemiology: the Danish National Database of Reimbursed Prescriptions.
        J Clin Epidemiol. 2012; 4: 303-313
        • Joensen AM
        • Jensen MK
        • Overvad K
        • et al.
        Predictive values of acute coronary syndrome discharge diagnoses differed in the Danish National Patient Registry.
        J Clin Epidemiol. 2009; 62: 188-194
        • Charlson ME
        • Pompei P
        • Ales KL
        • et al.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Thygesen SK
        • Christiansen CF
        • Christensen S
        • et al.
        The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients.
        BMC Med Res Methodol. 2011; 11: 83
        • Kristensen AMD
        • Bovin A
        • Zwisler AD
        • et al.
        Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial.
        Trials. 2020; 21: 415
        • Rosello X
        • Raposeiras-Roubin S
        • Latini R
        • et al.
        Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT).
        Eur Heart J Cardiovasc Pharmacother. 2022; 8: 291-301
        • Maqsood MH
        • Alam M
        • Atar D
        • et al.
        Efficacy of long-term oral beta-blocker therapy in patients who underwent percutaneous coronary intervention for ST-segment elevation myocardial infarction with preserved left ventricular ejection fraction: a systematic review and meta-analysis.
        J Cardiovasc Pharmacol. 2021; 77: 87-93
        • Park JJ
        • Kim SH
        • Kang SH
        • et al.
        Effect of beta-blockers beyond 3 years after acute myocardial infarction.
        J Am Heart Assoc. 2018; 7
        • Shavadia JS
        • Holmes DN
        • Thomas L
        • et al.
        Comparative effectiveness of beta-blocker use beyond 3 years after myocardial infarction and long-term outcomes among elderly patients.
        Circ Cardiovasc Qual Outcomes. 2019; 12e005103
        • Adelborg K
        • Sundbøll J
        • Munch T
        • et al.
        Positive predictive value of cardiac examination, procedure and surgery codes in the Danish National Patient Registry: a population-based validation study.
        BMJ Open. 2016; 6e012817